Have any head‑to‑head studies compared the efficacy and safety outcomes of two biologic agents in patients with inflammatory bowel disease (IBD), such as ulcerative colitis or Crohn’s disease?

Head-to-Head Biologic Comparisons in IBD

Yes, two major head-to-head randomized controlled trials have directly compared biologic agents in IBD: VARSITY (vedolizumab vs adalimumab in ulcerative colitis) and SEAVUE (ustekinumab vs adalimumab in Crohn's disease). 1

Direct Head-to-Head Trial Evidence

Ulcerative Colitis

• VARSITY demonstrated superiority of vedolizumab over adalimumab for achieving clinical and endoscopic remission in moderate-to-severe UC 1
• This finding is supported by network meta-analysis showing vedolizumab's efficacy advantage over adalimumab in biologic-naïve UC patients 1
• Vedolizumab also demonstrated lower risk of serious infections compared to TNF antagonists in UC patients (OR 0.68,95% CI 0.56-0.83) 2
• However, criticism exists regarding lack of uniform steroid-tapering protocols potentially influencing outcomes 1

Crohn's Disease

• SEAVUE failed to demonstrate superiority of ustekinumab over adalimumab for achieving symptom-based remission in moderate-to-severe CD 1
• The trial has been criticized for high remission rates in an early-disease, moderately active cohort that may not represent routine practice 1
• Network meta-analysis suggests infliximab combined with azathioprine or adalimumab monotherapy are preferred first-line options for inducing remission in biologic-naïve CD 3
• For biologic-exposed CD patients, adalimumab (after infliximab loss of response) or risankizumab are preferred for induction of remission 3

Comparative Safety Data

Infection Risk Profiles

• Ustekinumab demonstrated lower serious infection risk versus TNF antagonists (OR 0.49,95% CI 0.25-0.93) and versus vedolizumab (OR 0.40,95% CI 0.17-0.93) in CD patients 2
• No significant difference in serious infection risk between vedolizumab and TNF antagonists in CD (OR 1.03,95% CI 0.78-1.35) 2
• Age, sex, prior biologic exposure, and monotherapy use did not influence these safety associations 2

Real-World Observational Comparisons

TNF Antagonist Comparisons

• Multiple observational studies favor infliximab over adalimumab in real-world cohorts, though not universally 1
• This efficacy difference does not appear related to weight-based dosing or induction/maintenance dose variations 1

JAK Inhibitor Comparisons

• Upadacitinib demonstrated superior efficacy to tofacitinib and filgotinib in biologic-naïve UC patients through network meta-analysis 1
• Real-world cohort studies support this superiority finding 1
• Tofacitinib showed superior efficacy to vedolizumab in biologic-exposed patients for endoscopic improvement and histologic healing 1

IL-23 Inhibitor Comparisons

• Risankizumab demonstrated superiority over mirikizumab in biologic-naïve UC patients 1

Biologic-Exposed Population Findings

• Upadacitinib, tofacitinib, and ustekinumab are superior to vedolizumab in patients with prior biologic failure 1
• Ustekinumab superiority over vedolizumab is consistent with phase 3 trial signals: vedolizumab benefit over placebo decreased from 16.5% (TNF-naïve) to 6.5% (TNF-exposed), while ustekinumab maintained similar benefit (11.5% vs 8.5%) 1

Fistulizing Crohn's Disease

• Infliximab was superior to adalimumab for inducing fistula response (OR 0.24,95% CI 0.06-0.99) but not remission 4
• TNF antagonists as a class are superior to placebo for both fistula response (OR 0.51,95% CI 0.35-0.75) and remission (OR 0.36,95% CI 0.22-0.58) 4
• Ustekinumab is effective for fistula response but not remission when compared to placebo 4
• Infliximab remains the preferred first-line treatment for fistulizing CD based on available evidence 4

Critical Limitations

• Only two completed head-to-head RCTs exist despite the expanding therapeutic armamentarium 1
• Most comparative data derive from network meta-analyses and observational studies with inherent methodological limitations 1
• Real-world dose optimization strategies (early therapeutic drug monitoring, combination therapy, extended induction) are not captured in standard trial designs 1
• Prior exposure to specific drug classes may affect subsequent within-class efficacy, but this remains poorly characterized 1